C. D'Orazio

Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status

C. Ficorella, K. Cannita, A. Tessitore, 2022, Cancers.

Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice

A. Marchetti, F. Buttitta, C. Ficorella, 2019, OncoTargets and therapy.

Weekly alternate intensive regimen FirB/FOx in metastatic colorectal cancer patients: an update from clinical practice

A. Marchetti, C. Ficorella, A. Parisi, 2019 .

Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study.

N. Tinari, G. Tortora, C. Ficorella, 2021, Clinical colorectal cancer.

Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study

G. Tortora, C. Ficorella, A. Parisi, 2021, Frontiers in Oncology.